Kodiak Sciences, Inc. (KOD)
100.40
+3.36
(+3.46%)
USD |
NASDAQ |
Oct 29, 16:00
99.85
-0.55
(-0.55%)
After-Hours: 20:00
Kodiak Sciences Enterprise Value : 6.335B for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 6.335B |
| October 28, 2026 | 6.124B |
| October 27, 2026 | 5.765B |
| October 26, 2026 | 5.657B |
| October 23, 2026 | 5.533B |
| October 22, 2026 | 5.416B |
| October 21, 2026 | 5.538B |
| October 20, 2026 | 5.868B |
| October 19, 2026 | 5.766B |
| October 16, 2026 | 5.415B |
| October 15, 2026 | 5.564B |
| October 14, 2026 | 5.122B |
| October 13, 2026 | 5.784B |
| October 12, 2026 | 6.263B |
| October 09, 2026 | 6.302B |
| October 08, 2026 | 5.949B |
| October 07, 2026 | 5.749B |
| October 06, 2026 | 5.829B |
| October 05, 2026 | 5.921B |
| October 02, 2026 | 5.961B |
| October 01, 2026 | 6.213B |
| September 30, 2026 | 5.983B |
| September 29, 2026 | 5.752B |
| September 28, 2026 | 5.677B |
| September 25, 2026 | 2.059B |
| Date | Value |
|---|---|
| September 24, 2026 | 2.114B |
| September 23, 2026 | 2.007B |
| September 22, 2026 | 2.151B |
| September 21, 2026 | 2.064B |
| September 18, 2026 | 2.082B |
| September 17, 2026 | 2.091B |
| September 16, 2026 | 2.086B |
| September 15, 2026 | 2.100B |
| September 14, 2026 | 2.109B |
| September 11, 2026 | 2.093B |
| September 10, 2026 | 2.092B |
| September 09, 2026 | 2.149B |
| September 08, 2026 | 2.230B |
| September 04, 2026 | 2.249B |
| September 03, 2026 | 2.311B |
| September 02, 2026 | 2.383B |
| September 01, 2026 | 2.355B |
| August 31, 2026 | 2.374B |
| August 28, 2026 | 2.397B |
| August 27, 2026 | 2.485B |
| August 26, 2026 | 2.498B |
| August 25, 2026 | 2.506B |
| August 24, 2026 | 2.365B |
| August 21, 2026 | 2.435B |
| August 20, 2026 | 2.530B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 79.36B |
| AbbVie, Inc. | 578.15B |
| Mirum Pharmaceuticals, Inc. | 5.919B |
| ACADIA Pharmaceuticals, Inc. | 2.691B |
| Alnylam Pharmaceuticals, Inc. | 22.70B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -65.64M |
| Total Expenses (Quarterly) | 65.64M |
| EPS Diluted (Quarterly) | -1.048 |
| Earnings Yield | -4.18% |
| Normalized Earnings Yield | -4.176 |